Literature DB >> 9526144

Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.

C R Rush1, S H Kollins, P J Pazzaglia.   

Abstract

The discriminative-stimulus and participate-rated effects of a range of doses of d-amphetamine (2.5-20 mg), methylphenidate (5-40 mg), bupropion (50-400 mg), and triazolam (0.0625-0.5 mg) were tested in 5 humans trained to discriminate between oral d-amphetamine (20 mg) and placebo. d-Amphetamine and methylphenidate generally dose dependently increased drug-appropriate responding. Bupropion and triazolam on average occasioned less than or equal to 40% drug-appropriate responding. d-Amphetamine, methylphenidate, and bupropion produced stimulant-like participant-rated effects, while triazolam produced sedative-like effects. These results further demonstrate that the acute behavioral effects of d-amphetamine and methylphenidate overlap extensively in humans, which is concordant with preclinical studies. Bupropion produced some d-amphetamine-like, participant-rated drug effects but did not occasion significant levels of d-amphetamine-appropriate responding. These findings are concordant with previous findings of a dissociation between the discriminative-stimulus and participant-rated effects of drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9526144     DOI: 10.1037//1064-1297.6.1.32

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  35 in total

Review 1.  Agonist replacement therapy for cocaine dependence: a translational review.

Authors:  Craig R Rush; William W Stoops
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

3.  Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Michael J Wesley; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

4.  Effects of d-amphetamine in human models of information processing and inhibitory control.

Authors:  Mark T Fillmore; Thomas H Kelly; Catherine A Martin
Journal:  Drug Alcohol Depend       Date:  2005-02-14       Impact factor: 4.492

Review 5.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

6.  Mu opioid mediated discriminative-stimulus effects of tramadol: an individual subjects analysis.

Authors:  Justin C Strickland; Craig R Rush; William W Stoops
Journal:  J Exp Anal Behav       Date:  2015-02-09       Impact factor: 2.468

Review 7.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

8.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 9.  Human drug discrimination: A primer and methodological review.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; Craig R Rush
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

10.  Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans.

Authors:  William W Stoops; Andrea R Vansickel; Joshua A Lile; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2007-04-05       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.